Eton Pharmaceuticals, Inc. officer Ipek Erdogan-Trinkaus filed a Form 144 notice of proposed sale of 3,500 shares of common stock, with an approximate sale date of November 10, 2026, through Raymond James & Associates, Inc.

Key Highlights

  • Seller: Ipek Erdogan-Trinkaus, an officer of Eton Pharmaceuticals, Inc.
  • Shares proposed for sale: 3,500 shares of common stock, with an aggregate market value of $235,937.31 according to the filing.
  • Broker: Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg, FL 33716.
  • Shares outstanding: 282,889,941 shares of common stock reported as outstanding in the filing.
  • Acquisition: The 3,500 shares were acquired on January 12, 2026, via a grant from the issuer, with payment also noted as a grant on January 12, 2026.
  • Prior sales: The filing reports nothing to report for securities sold during the past 3 months.
  • Exchange: NASDAQ:ETON, as identified in the filing.

Proposed Rule 144 Sale by Eton Pharmaceuticals Officer

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission on November 10, 2026, Ipek Erdogan-Trinkaus, identified as an officer of Eton Pharmaceuticals, Inc. (NASDAQ:ETON), proposes to sell 3,500 shares of the company's common stock. The aggregate market value of the shares to be sold is listed as $235,937.31 in the filing. The approximate date of the proposed sale is November 10, 2026, and the transaction is to be executed through Raymond James & Associates, Inc.

The filing discloses that the 3,500 shares subject to this notice were acquired on January 12, 2026, through a grant from the issuer. The nature of acquisition is listed as "GRANT," and payment is similarly described as a grant on that same date. The filing reports that no securities of the issuer were sold by this person during the past three months.

The filing was signed by Rashida Mitchell, described as "duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Ipek Erdogan-Trinkaus." Eton Pharmaceuticals, Inc. is headquartered at 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7278, and carries SEC File Number 001-38738. The company had 282,889,941 shares of common stock outstanding as reported in the notice.

What Was Disclosed

Eton Pharmaceuticals officer Ipek Erdogan-Trinkaus filed a Form 144 on November 10, 2026, proposing to sell 3,500 grant-acquired common shares with an aggregate market value of $235,937.31, with no sales reported in the prior three months.